Current Diabetes Reports

, Volume 7, Issue 3, pp 235–241 | Cite as

Glycotoxins in the diet promote diabetes and diabetic complications



Oxidant stress underlies diabetes and diabetic complications, including cardiovascular, renal, and retinal disease. Advanced glycation end products (AGEs), or glycotoxins, are a significant contributor to oxidant stress in diabetes. The diet is a major, unrecognized source of AGEs. Importantly, reduction of dietary AGEs decreases circulating inflammatory markers in both diabetic patients and prediabetic patients and complications in animal models. This beneficial outcome requires only a 50% decrease in dietary AGEs, making this necessary intervention practical and inexpensive.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group [no authors listed]. N Engl J Med 1993, 329:977–986.Google Scholar
  2. 2.
    Monnier VM, Bautista O, Kenny D, et al.: Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes. Diabetes 1999, 48:870–880.PubMedCrossRefGoogle Scholar
  3. 3.
    Maillard LC: Action des acides amines sur les sucres: formation des malaniodines par voie methodique. C R Acad Sci 1912, 154:66–68.Google Scholar
  4. 4.
    Cai W, Gao QD, Zhu L, et al.: Oxidative stress-inducing carbonyl compounds from common foods: novel mediators of cellular dysfunction. Mol Med 2002, 8:337–346.PubMedGoogle Scholar
  5. 5.
    Goldberg T, Cai W, Peppa M, et al.: Advanced glycoxidation endproducts in commonly consumed foods. J Am Diet Assoc 2004, 104:1287–1291.PubMedCrossRefGoogle Scholar
  6. 6.
    Vlassara H, Cai W, Crandall J, et al.: Inflammatory mediators are induced by dietary glycotoxins: a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A 2002, 99:15596–15601.PubMedCrossRefGoogle Scholar
  7. 7.
    Frye EB, Degenhardt TP, Thorpe SR, Baynes JW: Role of the Maillard reaction in aging of tissue proteins. Advanced glycation end product-dependent increase in imidazolium cross-links in human lens proteins. J Biol Chem 1998, 273:18714–18719.PubMedCrossRefGoogle Scholar
  8. 8.
    Miyata T, van Ypersele C, Kurokawa K, Baynes JW: Alterations in nonenzymatic biochemistry in uremia: origin and significance of “carbonyl stress” in long-term uremic complications. Kidney Int 1999, 55:389–399.PubMedCrossRefGoogle Scholar
  9. 9.
    Bucala R, Makita Z, Koschinsky T, et al.: Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci U S A 1993, 90:6434–6438.PubMedCrossRefGoogle Scholar
  10. 10.
    Abordo EA, Minhas HS, Thornalley PJ: Accumulation of alpha-oxoaldehydes during oxidative stress: a role in cytotoxicity. Biochem Pharmacol 1999, 58:641–648.PubMedCrossRefGoogle Scholar
  11. 11.
    Vander Jagt DL, Hunsaker LA: Methylglyoxal metabolism and diabetic complications: roles of aldose reductase, glyoxalase-I, betaine aldehyde dehydrogenase and 2-oxoaldehyde dehydrogenase. Chem Biol Interact 2003, 143–144; 341–351.Google Scholar
  12. 12.
    Anderson MM, Requena JR, Crowley JR, et al.: The myeloperoxidase system of human phagocytes generates N(epsilon)-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest 1999, 104:103–113.PubMedGoogle Scholar
  13. 13.
    Dumitriu IE, Baruah P, Valentinis B, et al.: Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol 2005, 174:7506–7515.PubMedGoogle Scholar
  14. 14.
    Hori O, Brett J, Slattery T, et al.: The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of RAGE and amphoterin in the developing nervous system. J Biol Chem 1995, 270:25752–25761.PubMedCrossRefGoogle Scholar
  15. 15.
    Kaneko M, Bucciarelli L, Hwang YC, et al.: Aldose reductase and AGE-RAGE pathways: key players in myocardial ischemic injury. Ann N Y Acad Sci 2005, 1043:702–709.PubMedCrossRefGoogle Scholar
  16. 16.
    Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813–820.PubMedCrossRefGoogle Scholar
  17. 17.
    Sandu O, Song K, Cai W, et al.: Insulin resistance and type 2 diabetes in high-fat fed mice is linked to high glycotoxin intake. Diabetes 2005, 54:2314–2319.PubMedCrossRefGoogle Scholar
  18. 18.
    Lin RY, Choudhury RP, Cai W, et al.: Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis 2003, 168:213–220.PubMedCrossRefGoogle Scholar
  19. 19.
    Zheng F, He C, Cai W, et al.: Prevention of diabetic nephropathy in mice by a diet low in glycoxidation products. Diabetes Metab Res Rev 2002, 18:224–237.PubMedCrossRefGoogle Scholar
  20. 20.
    Koschinsky T, He CJ, Mitsuhashi T, et al.: Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A 1997, 94:6474–6479.PubMedCrossRefGoogle Scholar
  21. 21.
    Uribarri J, Peppa M, Cai W, et al.: Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol 2003, 14:728–731.PubMedCrossRefGoogle Scholar
  22. 22.
    Uribarri J, Cai W, Peppa M, et al.: Circulating glycotoxins and dietary AGEs: two links to inflammatory response, oxidative stress and aging. J Gerontol 2007, In press.Google Scholar
  23. 23.
    Vlassara H: Advanced glycation in health and disease: role of the modern environment. Ann N Y Acad Sci 2005, 1043:452–460.PubMedCrossRefGoogle Scholar
  24. 24.
    Martindale JL, Holbrook NJ: Cellular response to oxidative stress: signaling for suicide and survival. J Cell Physiol 2002, 192:1–15.PubMedCrossRefGoogle Scholar
  25. 25.
    Vlassara H, Palace MR: Diabetes and advanced glycation endproducts. J Intern Med 2002, 251:87–101.PubMedCrossRefGoogle Scholar
  26. 26.
    Lee CK, Klopp RG, Weindruch R, Prolla TA: Gene expression profile of aging and its retardation by caloric restriction. Science 1999, 285:1390–1393.PubMedCrossRefGoogle Scholar
  27. 27.
    Harris TB, Ferrucci L, Tracy RP, et al.: Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999, 106:506–512.PubMedCrossRefGoogle Scholar
  28. 28.
    Vlassara H, Brownlee M, Manogue K, et al.: Cachectin/TNF and IL-1 induced by glucose-modified proteins: Role in normal tissue remodeling. Science 1988, 240:1546–1548.PubMedCrossRefGoogle Scholar
  29. 29.
    Shangan N, Bruce WB, Poon R, O’Brien: Toxicity of glyoxals—role of oxidative stress, metabolic detoxification and thiamine deficiency. Biochem Soc Trans 2003, 31:1390–1393.CrossRefGoogle Scholar
  30. 30.
    Liu H, Zheng F, Cao Q, et al.: Amelioration of oxidant stress by the defensin lysozyme. Am J Physiol 2006, 290:E824–E832.Google Scholar
  31. 31.
    Lu C, He JC, Cai W, et al.: Advanced glycation end product (AGE) receptor 1 is a negative regulator of the inflammatory response to advanced glycation endproducts in mesangial cells. Proc Natl Acad Sci U S A 2004, 101:11767–11772.PubMedCrossRefGoogle Scholar
  32. 32.
    Schmidt AM, Hori O, Brett J, et al.: Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb 1994, 14:1521–1528.PubMedGoogle Scholar
  33. 33.
    He C, Koschinsky T, Buenting C, Vlassara H: Presence of diabetic complications in type 1 diabetic patients correlates with low expression of mononuclear AGE-receptor-1 and elevated serum AGE. Mol Med 2001, 7:159–168.PubMedGoogle Scholar
  34. 34.
    Wautier MP, Chappey O, Corda S, et al.: Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 2001, 280:E685–E694.PubMedGoogle Scholar
  35. 35.
    Huebschmann AG, Judith G, Regensteiner JG, et al.: Diabetes and advanced glycoxidation end products. Diabetes Care 2006, 29:1420–1432.PubMedCrossRefGoogle Scholar
  36. 36.
    Foley RN, Murray AM, Li S, et al.: Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005, 16:489–495.PubMedCrossRefGoogle Scholar
  37. 37.
    Murata T, Nagai R, Ishibashi T, et al.: The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas. Diabetologia 1997, 40:764–769.PubMedCrossRefGoogle Scholar
  38. 38.
    McCance DR, Dyer DG, Dunn JA, et al.: Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest 1993, 91:2470–2478.PubMedCrossRefGoogle Scholar
  39. 39.
    Beckman JA, Creager MA, Libby P: Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. J Am Med Assoc 2002, 287:2570–2581.CrossRefGoogle Scholar
  40. 40.
    Basta G, Schmidt AM, De Caterina R: Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res 2004, 63:582–592.PubMedCrossRefGoogle Scholar
  41. 41.
    Airaksinen KE, Salmela PI, Linnaluoto MK, et al.: Diminished arterial elasticity in diabetes: association with fluorescent advanced glycosylation end products in collagen. Cardiovasc Res 1993, 27:942–945.PubMedGoogle Scholar
  42. 42.
    Schram MT, Henry RM, van Dijk RA, et al.: Increased central artery stiffness in impaired glucose metabolism and type 2 diabetes: the Hoorn Study. Hypertension 2004, 43:176–181.PubMedCrossRefGoogle Scholar
  43. 43.
    Wolffenbuttel BH, Boulanger CM, Crijns FR, et al.: Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci U S A 1998, 95:4630–4634.PubMedCrossRefGoogle Scholar
  44. 44.
    Soulis T, Cooper ME, Sastra S, et al.: Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats. Diabetologia 1997, 40:1141–1151.PubMedCrossRefGoogle Scholar
  45. 45.
    Hammes HP, Strodter D, Weiss A, et al.: Secondary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model. Diabetologia 1995, 38:656–660.PubMedGoogle Scholar
  46. 46.
    Brownlee M, Vlassara H, Kooney A, et al.: Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986, 232:1629–1632.PubMedCrossRefGoogle Scholar
  47. 47.
    Degenhardt TP, Alderson NL, Arrington DD, et al.: Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 2002, 61:939–950.PubMedCrossRefGoogle Scholar
  48. 48.
    Hammes HP, Du X, Edelstein D, et al.: Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003, 9:294–299.PubMedCrossRefGoogle Scholar
  49. 49.
    Cai W, He JC, Zhu L, et al.: Enhanced AGER1 expression, low oxidant stress and extended lifespan in mice exposed to a low glycoxidant diet. Am J Pathol 2007, In press.Google Scholar

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  1. 1.Division of Experimental Diabetes and Aging, Department of GeriatricsMount Sinai School of MedicineNew YorkUSA

Personalised recommendations